Home Healthcare Pharmaceuticals United States Influenza Treatment Market

United States Influenza Treatment Market Size, Share & Trends Analysis Report By Product (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy) and Forecasts, 2026-2034

Last Updated: September 01, 2026 | Author: Debashree Bora | Format:

United States Influenza Treatment Market Size

The United States influenza treatment market size was valued at USD 7.18 billion in 2025 and is projected to grow from USD 7.79 billion in 2026 to reach USD 14.96 billion by 2034, growing at a CAGR of 8.50% during the forecast period 2026–2034.

The market’s steady growth is primarily attributed to the continuous development of antiviral treatments, rising prevalence, and significant healthcare infrastructure investments. As the healthcare landscape evolves, incorporating new treatment options, including locally acting antiviral agents and advancements in vaccine development, will contribute to expanding the market.

United States Influenza Treatment Market Size

Download a Free Sample To learn more about this report.

United States Influenza Treatment Market Segmentation Analysis

By Drug Type

Locally Acting Antiviral Agents dominate the drug type segment and are expected to grow at a CAGR of 2.5% over the forecast period. These drugs are designed to target influenza viruses directly at the site of infection, offering effective treatment with fewer side effects. The market for these agents is gaining momentum due to their ability to minimize systemic effects, making them a preferred choice for specific patient demographics. Advancements in drug formulation and developing new treatment options by companies such as Roche and Gilead Sciences will further propel this segment's growth.

United States Influenza Treatment Market Size By Segments

Request Customizationto receive a tailored report.

By End User

Hospitals and Clinics lead the end-user segment and are expected to grow at a CAGR of 2.9% during the forecast period, driven by the increasing demand for treatments in clinical settings. Hospitals are central to delivering healthcare services in the United States, and their role in managing flu patients is vital. During flu season, hospital emergency rooms experience a surge in patient visits, increasing the need for antiviral therapies and influenza vaccines. Furthermore, hospitals' extensive infrastructure and capacity to manage severe cases of influenza, particularly in intensive care units, contribute to the growth of this segment.

United States Influenza Treatment Market Share By Segments

Speak to an Analystto discuss market opportunities.

United States Influenza Treatment Market Regional Insights

The market is characterized by diverse healthcare infrastructure across urban and rural areas, influencing the accessibility and adoption of influenza treatment options.

  • New York City, with its large population and significant healthcare resources, is a key player in the U.S. influenza treatment market. The city’s hospitals, such as the NewYork-Presbyterian Hospital and Mount Sinai Health System, are actively involved in treating influenza patients and promoting flu vaccinations. Additionally, New York’s high healthcare expenditure allows for quicker adoption of new antiviral treatments, keeping the market dynamic. The state's public health initiatives, including seasonal flu vaccination drives, contribute to a more robust market for influenza treatments.
  • Los Angeles is another crucial market for influenza treatments, supported by a robust healthcare system and many clinics and hospitals. The region's population is diverse, with a significant proportion of individuals at high risk for influenza-related complications, such as older people and those with chronic conditions. Hospitals like Cedars-Sinai and Keck Medicine of USC are at the forefront of treatment, offering advanced antiviral therapies. The city's focus on healthcare innovation and flu prevention programs further strengthens its position in the market.
  • Chicago's healthcare system is highly integrated, with large hospitals like the Northwestern Memorial Hospital and the University of Chicago Medicine playing pivotal roles in treating flu patients. Chicago also has a significant network of outpatient clinics, which are increasingly adopting antiviral treatments for influenza patients. The city’s commitment to public health initiatives, such as flu shot campaigns and awareness programs, supports the growth of the influenza treatment market.
  • In Houston, home to the Texas Medical Center the largest medical complex in the world demand for treatments is driven by the city’s large, diverse population and advanced healthcare infrastructure. Hospitals like the MD Anderson Cancer Center and the Houston Methodist Hospital are major players in influenza care. The city's central role in medical research and healthcare provision and a high patient volume during flu season ensure a steady demand for antiviral medications.
  • Miami, with its tropical climate and large elderly population, sees a heightened incidence of influenza outbreaks during the flu season. Hospitals like the University of Miami Health System and Jackson Memorial Hospital provide extensive treatment for flu patients, including antiviral medications. Additionally, Miami’s focus on preventive healthcare, including vaccination campaigns, drives the demand for effective treatments.

List of Key and Emerging Players in United States Influenza Treatment Market

Roche Holding AG
GlaxoSmithKline plc
AstraZeneca plc
Sanofi S.A.
Seqirus (a subsidiary of CSL Limited)
Johnson & Johnson
Pfizer Inc.
Novartis International AG
Daiichi Sankyo Company, Limited
Mylan N.V.

Key Industry Developments

June 2026
Roche expanded its influenza portfolio by strengthening U.S. commercial initiatives for Xofluza® (baloxavir marboxil), supporting broader access to single-dose influenza treatment during the seasonal flu period.
May 2026
Pfizer Inc. expanded research collaborations focused on next-generation antiviral therapies for respiratory viral infections, including influenza, to accelerate future treatment innovation.
March 2026
Shionogi & Co., Ltd. advanced the development of novel antiviral candidates targeting influenza viruses through expanded global clinical research programs.
August 2025
Genentech strengthened collaborations with U.S. healthcare organizations to improve awareness of early influenza diagnosis and timely antiviral treatment.

Report Scope

Segmentation

By Product 4
  • Peramivir
  • Zanamivir
  • Oseltamivir Phosphate
  • Baloxavir Marboxil
By Distribution Channel 2
  • Retail Pharmacy
  • Hospital Pharmacy
Competitive Coverage Roche Holding AG · GlaxoSmithKline plc · AstraZeneca plc · Sanofi S.A. · Seqirus (a subsidiary of CSL Limited)
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

Straits research predicts that the United States influenza treatment market size was valued at USD 7.18 billion in 2025 and is projected to grow from USD 7.79 billion in 2026 to reach USD 14.96 billion by 2034.
The United States market growth rate growing at a 8.50% from 2026 to 2034.
The rising incidence of seasonal influenza outbreaks, is a key growth factor driving advancements in influenza treatment.
New York City holds the largest market share with its large population and significant healthcare resources.
Currently, the locally acting antiviral agents segment dominates the market.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
Trusted by Industry Leaders
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now